Sat, Aug 30, 2014, 1:24 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OneBeacon Insurance Group, Ltd. Message Board

snogreen 131 posts  |  Last Activity: Aug 28, 2014 9:22 AM Member since: Aug 30, 2000
  • Reply to


    by bull1863 Jun 23, 2014 8:42 AM
    snogreen snogreen Jun 23, 2014 9:06 AM Flag

    I don't mind if it takes 6 months to set up, as long as Finkel isn't involved in trial design or setup. Do it right. I also pray that Lee's is in touch with Ora Inc on trial design in terms of endpoints. There were several areas withing the cornea you can look at. Unfortunately, Ora & RGRX went with the one area for primary endpoint where pre clinical showed efficacy in animal study. They didn't get statistical there..but did get over the top statistical P values on two aother areas of the cornea. But since they were not designatd as areas for endpoints in the phase 2, they cannot be considered by the FDA..thus most investors believe the trial flopped.. let's just pray that Ora Inc is feeding them the imprtant human data they got where the statistcal results were a winner for TB 4.

    Can anyone find the actual trial listing and description? How many pts? Blinded? Dose levels? And most important.what are the primary and secondary endpoints……choss the same where Ora got good result??

  • Reply to

    new abstract,neuro/sinal

    by snogreen Jun 22, 2014 3:24 PM
    snogreen snogreen Jun 22, 2014 3:30 PM Flag

    Yahoo cut part off. Why hasn't Henry Ford moved on doing a small Phs 2 neuro area? They've had about 6 people working with TB 4 for about 6-7 years now……and have written a bunch of abstracts on what they found in the early work. So that is a lot of salaries and reserarch monies and expenses they paid….for what? Unless they do something with it..…what good was it all? Nothing.

  • Thymosin β4 (Tβ4) has many physiological functions that are highly relevant to spinal cord injury (SCI), including neuronal survival, anti-inflammation, wound repair promotion, and angiogenesis. The present study investigated the therapeutic value of Tβ4 in SCI, with a focus on its neuroprotective, anti-inflammatory, and vasculoprotective properties. Tβ4 or a saline control was administered by intraperitoneal injection 30 min, 3 days, or 5 days after SCI with mild compression in rat. Locomotor recovery was tested with the Basso-Beattie-Bresnahan scale and a footprint analysis. All behavioral assessments were markedly improved with Tβ4 treatment. Histological examination at 7 days post injury showed that the numbers of surviving neurons and oligodendrocytes were significantly increased in Tβ4-treated animals compared to saline-treated controls. Levels of myelin basic protein, a marker of mature oligodendrocytes, in Tβ4-treated rats were 57.8% greater than those in saline-treated controls. The expression of ED1, a marker of activated microglia/macrophages, was reduced by 36.9% in the Tβ4-treated group compared to that of the saline-treated group. Tβ4 treatment after SCI was also associated with a significant decrease in pro-inflammatory cytokine gene expression and a significant increase in the mRNA levels of IL-10 compared to the control. Moreover, the size of lesion cavity delineated by astrocyte scar in the injured spinal cord was markedly reduced in Tβ4-treated animals compared to saline-treated controls. Given the known safety of Tβ4 in clinical trials and its beneficial effects on SCI recovery, the results of this study suggested that Tβ4 is a good candidate for SCI treatment in humans.

  • snogreen snogreen Jun 19, 2014 3:47 PM Flag

    Thanks for sharing the abstract, bull.

  • Reply to

    Just sent letter to JJ

    by thebasiles777 Jun 16, 2014 12:03 PM
    snogreen snogreen Jun 16, 2014 1:25 PM Flag

    Forget a timeline chart…if someone wants a project, go back the about 25 years that Finkel-Tinkel has run RGRX (into the ground)…add up exactky how much we have paid him in salary, cash bonuses, 401-k match, health insurance, stock awards, option awards (all free)…….a travel account, expense account, foreign travel….and any other perks you can think of. Add it all up to one number and ask yourself, 'Was he worth it"

    We all know the answer. we are stuck with him because he is related to Goldstein. It's why Sigma Tau can't get rid of Finkelstein..he's related to Goldstein. And Goldstein won't allow it..because ST knows they need Goldstein.. if TB 4 is to ever work. From how I see it, Sigma Tau just abandoned anything to do with RGRX. Goldstein protects Finkel Dope… ST can't step in and do thinngs properly. So if ST can't do that, they just walk away and let chips fall where they may. ST has had no interest in buying any of the last few penny financing deals..and they have all the money in the world. They just walked away from RRGX. If Boveever attends a BOD meeting, he probably just listens on a phone.

  • Reply to

    Dutch Auction pretty much a flop...

    by copywrites Jun 16, 2014 10:46 AM
    snogreen snogreen Jun 16, 2014 12:54 PM Flag

    AHH, I see. I had to read all of release. SEB can't buy any open market stock till June 27. So we have 10 days if we wish. I took a shot and bought 5 shares down around 2887. I think they buy more come 27th.

  • Reply to

    Dutch Auction pretty much a flop...

    by copywrites Jun 16, 2014 10:46 AM
    snogreen snogreen Jun 16, 2014 12:49 PM Flag

    what is significance of June 26..10 days from now?

  • Reply to

    Just sent letter to JJ

    by thebasiles777 Jun 16, 2014 12:03 PM
    snogreen snogreen Jun 16, 2014 12:43 PM Flag

    He can't reply, because he'll hide behind Rule FD.

    You forgot to ask him what happened with Henry Ford? They have a 6 person research staff for a bunch of years now on TB 4 in neuro. RGRX said that theywoudl be #$%$ a small physician based trial in MS or neuro. what happened there?

    or what happned to another physician sponsored sever dry eye trial?

    OR? did RGRX apply for an FDA $$ Orphan grant???? for an EYE NK trial? will RGRX use Ora Inc for it?

    What are the Koreans doing/

    what does he think about AVON now selling a supposed TB 4 product?? What they now sell vaidates TB 4.

    Never forget you are dealing with a Finkel Dope. He has been at the helm close to 25 years. the only winner is him. It is not possible that he works even CLOSE to 8 hours a day. What is he possibly doing for hiis $125,000. nothing. I see no one cared at all about Goldsteins talk earlier today.

  • Reply to

    Dutch Auction pretty much a flop...

    by copywrites Jun 16, 2014 10:46 AM
    snogreen snogreen Jun 16, 2014 12:19 PM Flag

    You forget that SEB also has an open market stock buyback, on top of the dutch tender just finished. We don't know what they bought from $2400 to 2935 in the last month, open market. Trading volumes were above normal.

    If it comes down, I might nibble. Fact remains that Tyson paid almost 16 times EBIDTA for HSH. if SEB ever accepted a similar priced level for it's pork division, SEB is over $3,600 a share.

  • Reply to

    Down side is little here

    by thebasiles777 Jun 16, 2014 10:07 AM
    snogreen snogreen Jun 16, 2014 10:46 AM Flag

    I would entertain buying more, but why? Lee's isn't doing anything…….RGRX blew off attending a NICE scoping meeting…..Avon is out with a similar TB 4 product a handful of months after they were given patent. Show me ONE thing that RGRX mgmt did right, and I will buy. If I thought Finkel Dope coudl do anything correctly.and we have TWENTY FIVE YEARS OF EXPERIENCE WITH HIM…I would be happy to buy that 110,000 shares. But if I buy that 110k shares, I buy FINKELSTEIN, not TB 4. Give me a reason, please, too buy Finkelstein. Otherwise I sit and either win with what I have or take a total tax loss.

  • Reply to

    Article about new Avon cream

    by brewtsu Jun 16, 2014 5:41 AM
    snogreen snogreen Jun 16, 2014 9:43 AM Flag

    It is all basically hype by Avon. Their creme retails for 20 Pounds….or about $30.00 US…..A fully synthetic TB 4 peptide woudl have to cost a lot more to include.. Other issue is RGRXneeeds to use synthetic TB 4 peptide Fragments for cosmetic uses. I don't see any more work done by Finkel on the peptide fragments.

  • Reply to

    Article about new Avon cream

    by brewtsu Jun 16, 2014 5:41 AM
    snogreen snogreen Jun 16, 2014 6:53 AM Flag

    THat is pretty amazing. Just another example of Finkelstein incompetence. He's run RGRX for 20-25 years, and can't do a damned thing with TB 4..well, at least correctly. The results of the Avon creme look good….and the results are quoted by a Dr….but read carefully. The patent Avon has is NOT for TB 4, per se…but only in a way that the body produces more TB 4. Article says thet Avon looked at 2 million compounds to 'turn up the bodies own production". Finkel-Dope should buy a jar. If, on the label.Avon says they put in TB 4, then that is a patent violation and RGRX can sue. If Avon doesn't list TB 4, then that is okay. I don't know how Avon can turn up the body making TB 4 so much, that wrinkjles go away. but who knows. The upshot is that if by chance the Avon product takes off in sales and get good reviews, that bodes well for RGRX…..because the Avon product is not supposed to have any TB 4 in it (technically). What if a product comes that HAS a strong dose of synthetic TB 4…..RGRX.

  • Well, I see RGRX is doing another worthless thymosin symposium. It's just a boondoggle trip….for the same old, same old researchers….who do so for their own "job justification" this case - the "important research" they do on TB 4. Somehow they get funded year after year after year….and the highlight of their "years work" is that they get to "present" and a major "international symposium"……I am quite sure that is why Goldstein created these "symposiums"….he has a loyal cadre of TB 4 researchers, who do TB 4 research work for him. But these researchers have to "justify" their job ($$ research grants) and the way to do that is PUBLISH. But what happens if no one cares, no one will publish it? So the solution is that Goldstein creates his own "front"…he creates the "world symposium"……for "job justification" for TB 4 researchers…who tell their bosses that their work was recognized for a "SPEAKING" role at a MAJOR symposium in ROMA, Italy…"and may I please have 10 days off to attend and a stipend of $10,000 to present this important TB 4 work I do - to an international audience". But all it is is a "front" conference, which provides job justification "cover" to the same old, same old people. No big pharma gices a damn. Few come I bet.

    The one that does confuse me is Henry Ford. They are real. They have money. They have a small team that has worked on TB 4 for years. They have about 3 people speaking & coming - incluing the head, Dr. Michael Chopp. So WHY is it Henry Ford can't do a damn thing with a small TB 4 test in neutro or MS - ? Or coudl it be the Dr. Chopp is just another on the supossed TB 4 "job justification" research bandwagon"..and has no intention of doing a test…..but waits for another pharma to buy into his thesis? But henry ford is totally capable of doing a small Phs 2 see if a larger Phs 2 is warranted. Dr. Chopp seems to have no interest beyond his job justification that he does "research"….and he gets an Italian boondoggle included now.

  • snogreen snogreen Jun 11, 2014 6:08 AM Flag

    That is dry and dull as dishwater. It's the same as what RGRX just says in any SEC filing, talking about TB 4. Dull, dry and boilerplate.. It will be teh first speech of the conference and people will fall asleep. It is also a mistake for Goldstein to mention every possible disease indication known to man for TB 4……that will really turn off teh crowd…….a lunatic Dr. with a compound to cure all mans diseases, naturally. Focus on one or two..and barely mention others.

  • Reply to

    NITE very quiet here

    by snogreen Jun 10, 2014 11:12 AM
    snogreen snogreen Jun 10, 2014 12:43 PM Flag

    I siad that I thought it was a HUGE mistake for RGRX to NOT attend the scoping meeting. The NHS came right out and said that RGRX did not lift a finger for the TB 4 look see. But I also said early on when I found the NICE stuff, that NICE was going off only a phase 2 trial…and the NHS caught that and said no phase 3 has been done. But maybe it woudl have helped if they showed up to the meeting. who knows.

    This plenary speaking spot Goldstein got, at a big conference….is the biggest "face time" RGRX has ever gotten. They have nener gotten a speaking spot before, only poster spots. So to get a speaking spot is big…….but the FIRST UP plenary speaker to the whole conference, on the first day? HOW did he get that.

    There's a TON of money managed in Boston, and tons of biotech firms. I can't imagine that there won't be a lot of "industry" and "Investment" people attending…….and every one of them will hear Goldstein speak first to the whole conference. Let's hope he is a dynamic speaker.

  • Goldstein get's kudos or he pulled some strings somehow. This drug discovery conference in Boston….June 16-19…is a big one. At the Hynes convention center. All kinds of speakers and posters to chose from. but somehow Goldstein managed to get a Plenary speaker spot…not a poster spot or a breakout spot….Golldstein is a plenary speaker that is set to present to the whole auditorium. even more impressive is he get's the starting speech - on the first day…numero uno position….all there will be fresh and attentive.

    Let's hope some analysts and investment types attend this conference and they get intrigued by what Goldstein says.

  • NITE has ben quiet here recently.. I wonder if they have had other problems last couple days. Two smallish biotechs have exploded in last 2 days and both had huge short interests….so I bet NITE was also a lead MM in them..and knowing NITE they tend to stay short side. IDIX is being taken over by MRK….and the stock went from $6-$7 to about $17. A smaller similar bio, ACHN also tripled in value almost. And both of these names were a short sellers favorite. They got nailed big heres to hoping NITE was doing what they do, shorting bio names and they got creamed. It's not that they won't be around RGRX….but maybe for a while NITE has bigger problems on their hands with IDIX and ACHN exploding… that they don't have inclination to game, short and print RGRX down for a couple of pennies…if they were short IDIX and ACHN they got bigger money problems.

  • Reply to

    How to talk to these guys

    by mark_j_larry Jun 9, 2014 5:01 PM
    snogreen snogreen Jun 10, 2014 6:57 AM Flag

    I don't think SEB has an investor relations person.because between Bresky and Fidelity theyy are the "investors" of SEB They own over 80% of SEB. So SEB doesn't see the need to have an IR person…they are under the radar and do so on purpose. I doubt they'll talk to you……..even if you had contact info, like a phone no#….I don't think they'd talk..they use excuse they are in SEC regs of no talking while a self tender is in effect.

  • Remarkable. Hillshire will be sold to Tyson for $63 a share, about $7.7 billion…..or 15 x trailiong EBIDTA. You put those kinds of similar measures on the pork division of SEB…..and it could be worth over $4 billion alone. I'm sure bankers are calling SEB…..but the $1 million questions is, would Bresky sell his pork division if he was offered 12-14 times it's EBIDTA? he should, but would he? I don't know. He may not care about money….SEB has owned it a long time…maybe he thinks it would be worth more 10 years down the road……and maybe he has plans to put other "family" members into the SEB management fold (just as he was by his father)… if he wants more family "in"…he needs businesses for them to run..and pork is a winner for SEB.

    If SEB is buying open market stock, it would not behoove them to bid it to the $2,950 area. Back off buying now. If SEB is above $2,950 area… fewer will tender. I think even if they have "pre tendered." they have the right to withdraw before closing the 13th.

  • Reply to

    looks like 2950

    by snogreen Jun 4, 2014 1:22 PM
    snogreen snogreen Jun 4, 2014 1:58 PM Flag

    But is there any restriction by the SEC rules to buy open market shares while a registered tender off is in place?

    If SEB is allowed open market buys while tender is open..then, yes…they are buying. But keep in mind that teh SEC has rules on that too…I recall that the SEC states you can't account for more than 25% of any days volume. But you better check that….I think it is a 25% rule……but it still can be SEB oushing it up if they don't see stock coming in for tender. But most woudl come in the last few days anyways.

16.03+0.01(+0.06%)Aug 29 4:02 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.